You may have access to the free features available through My Research. You can save searches, save documents, create alerts and more. Please log in through your library or institution to check if you have access.
If you log in through your library or institution you might have access to this article in multiple languages.
Styles include MLA, APA, Chicago and many more. This feature may be available for free if you log in through your library or institution.
You may have access to it for free by logging in through your library or institution.
You may have access to different export options including Google Drive and Microsoft OneDrive and citation management tools like RefWorks and EasyBib. Try logging in through your library or institution to get access to these tools.
You might have access to the full article...
Try and log in through your institution to see if they have access to the full text.
Fosamax, (alendronate sodium), from Merck, is now available to increase bone mass in men who have osteoporosis. Dosage is a 10-mg tablet once daily. Since 1995, Fosamax has been marketed for the treatment of postmenopausal osteoporosis. Approximately 2 million men in the U.S. have osteoporosis.
